Horizon Therapeutics shareholders overwhelmingly approve acquisition by Amgen
Zolak         

More than 99% Horizon Therapeutics (NASDAQ:HZNP) shareholders who voted during a special meeting did so in favor of the company's acquisition by Amgen (NASDAQ:AMGN).
That figure represented about 76% of total Horizon (HZNP) shares.
The $28B acquisition is facing FTC scrutiny as the agency issued a "second request" to Amgen (AMGN) at the end of January for additional information.